Rivaroxaban
- Generic Name
- Rivaroxaban
- Brand Names
- Xarelto, Rivaroxaban Accord, Rivaroxaban Viatris (previously Rivaroxaban Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18ClN3O5S
- CAS Number
- 366789-02-8
- Unique Ingredient Identifier
- 9NDF7JZ4M3
- Background
Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, ...
- Indication
Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurre...
- Associated Conditions
- Cardiovascular Mortality, Deep Vein Thrombosis, Deep vein thrombosis recurrent, Major Adverse Cardiovascular Events, Myocardial Infarction, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Thrombosis, Venous Thromboembolism
- Associated Therapies
- -
Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery
- Conditions
- Interventions
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2012-08-23
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 632
- Registration Number
- NCT01344954
- Locations
- 🇦🇹
KRANKENHAUS DES BARMHER.SCHW.Linz, Linz, Austria
🇷🇺Federal State Healthcare Institution: Clinical Hospital #122 named after L.G. Sokolov under the Federal Medical-Biological Agency of Russia, Saint-Petersburg, Russian Federation
🇧🇪ZNA Antwerpen Locatie Middelheim, Antwerpen, Belgium
Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement
- Conditions
- Interventions
- First Posted Date
- 2010-03-29
- Last Posted Date
- 2017-03-17
- Lead Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
- Target Recruit Count
- 56
- Registration Number
- NCT01094886
An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation
- First Posted Date
- 2006-11-27
- Last Posted Date
- 2014-04-29
- Target Recruit Count
- 14269
- Registration Number
- NCT00403767
Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial)
- Conditions
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2012-10-04
- Target Recruit Count
- 3490
- Registration Number
- NCT00402597
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.